Investigation of lymphoma patients' EBV infection status.
10.7534/j.issn.1009-2137.2014.06.016
- Author:
Xiao-Yi WANG
1
,
2
;
Xi-Nan CEN
3
;
Han-Yun REN
4
Author Information
1. Department of Hematology, Peking University First Hospital, Beijing 100034, China
2. China-Japan Friendship Hospital, Beijing 100029, China.
3. Department of Hematology, Peking University First Hospital, Beijing 100034, China. E-mail: cenxn@aliyun. com.
4. Department of Hematology, Peking University First Hospital, Beijing 100034, China.
- Publication Type:Journal Article
- MeSH:
Epstein-Barr Virus Infections;
complications;
Herpesvirus 4, Human;
Humans;
Immunoblastic Lymphadenopathy;
Lymphoma;
virology;
Survival Analysis
- From:
Journal of Experimental Hematology
2014;22(6):1584-1590
- CountryChina
- Language:Chinese
-
Abstract:
This study was purposed to investigate the EBV infection status of lymphoma patients from January 2008 to April 2012 in the First Hospital of Peking University. All the candidates have been detected for EBV which was either peripheral blood EBV DNA or ISH EBER in pathology from January 2008 to April 2012. The information on their sex, age, pathological type, peripheral blood EBV DNA and ISH EBER was collected, the positive rate of different EBV tests was studied, and the different characteristics of the EBV(+) and EBV(-) group were also explored. And Kaplan-Meier and Cox survival analysis was applied to investigate the EBV's effect on overall survival of these patients. The results showed that among 169 lymphoma patients, the positive rates of EBV EBER in extranodal NK/T cell lymphoma, angioimmunoblastic T cell lymphoma and peripheral T-cell lymphoma were 84.8%, 72.7% and 40.0%, respectively, and were ranged as the top three. The positive rate of EBV in DLBCL was relatively lower (16.7%) than that in above three types of lymphoma. The positive rate of peripheral blood EBV DNA of the elderly EBV(+) DLBCL was 50%. One out of 10 HL patients was subjected to EBER detection, the result of which was positive. The positive rate of peripheral blood EBV DNA of HL was 10%. Both the T cell lymphoma proportion and the rate of B symptom were higher in EBV(+) group than in EBV(-) group. In all the EBER(+) cases, the difference of OS between EBV(+) and EBV(-) patients was statistically significant. In multiple-factor survival analysis, peripheral blood EBV DNA positive was an independent risk factor for poor prognosis in the patients with lymphoma. It is concluded that EBV is closely related to extranodal NK/T cell lymphoma, angioimmunoblastic T cell lymphoma and peripheral T-cell lymphoma. Peripheral blood EBV DNA positive is an independent risk factor for poor prognosis in lymphoma patients.
